304 related articles for article (PubMed ID: 20072801)
1. Phase II study of combination chemotherapy with irinotecan and cetuximab for pretreated metastatic colorectal cancer harboring wild-type KRAS.
Shitara K; Yokota T; Takahari D; Shibata T; Ura T; Utsunomiya S; Inaba Y; Yamaura H; Sato Y; Najima M; Kawai H; Tajika M; Sawaki A; Yatabe Y; Muro K
Invest New Drugs; 2011 Aug; 29(4):688-93. PubMed ID: 20072801
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines.
Shitara K; Yuki S; Yoshida M; Takahari D; Utsunomiya S; Yokota T; Sato Y; Inaba Y; Tajika M; Kawai H; Yamaura H; Kato M; Yamazaki K; Komatsu Y; Muro K
Invest New Drugs; 2012 Apr; 30(2):787-93. PubMed ID: 21174225
[TBL] [Abstract][Full Text] [Related]
3. Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status.
Kang MJ; Hong YS; Kim KP; Kim SY; Baek JY; Ryu MH; Lee JL; Chang HM; Kim MJ; Chang HJ; Kang YK; Kim TW
Invest New Drugs; 2012 Aug; 30(4):1607-13. PubMed ID: 21706149
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for pre-treated metastatic colorectal cancer harboring wild-type KRAS.
Shitara K; Yokota T; Takahari D; Shibata T; Ura T; Komatsu Y; Yuki S; Yoshida M; Takiuchi H; Utsunomiya S; Yatabe Y; Muro K
Jpn J Clin Oncol; 2010 Jul; 40(7):699-701. PubMed ID: 20304778
[TBL] [Abstract][Full Text] [Related]
5. Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial.
Élez E; Kocáková I; Höhler T; Martens UM; Bokemeyer C; Van Cutsem E; Melichar B; Smakal M; Csőszi T; Topuzov E; Orlova R; Tjulandin S; Rivera F; Straub J; Bruns R; Quaratino S; Tabernero J
Ann Oncol; 2015 Jan; 26(1):132-140. PubMed ID: 25319061
[TBL] [Abstract][Full Text] [Related]
6. Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome.
García-Foncillas J; Díaz-Rubio E
Clin Transl Oncol; 2010 Aug; 12(8):533-42. PubMed ID: 20709651
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of biweekly cetuximab and irinotecan as third-line therapy for pretreated KRAS exon 2 wild-type colorectal cancer.
Osumi H; Shinozaki E; Mashima T; Wakatsuki T; Suenaga M; Ichimura T; Ogura M; Ota Y; Nakayama I; Takahari D; Chin K; Miki Y; Yamaguchi K
Cancer Sci; 2018 Aug; 109(8):2567-2575. PubMed ID: 29908105
[TBL] [Abstract][Full Text] [Related]
8. Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: clinical outcome according to KRAS and BRAF mutational status.
Fornaro L; Baldi GG; Masi G; Allegrini G; Loupakis F; Vasile E; Cupini S; Stasi I; Salvatore L; Cremolini C; Vincenzi B; Santini D; Tonini G; Graziano F; Ruzzo A; Canestrari E; Magnani M; Falcone A
Crit Rev Oncol Hematol; 2011 Jun; 78(3):243-51. PubMed ID: 20619672
[TBL] [Abstract][Full Text] [Related]
9. Second-line cetuximab/irinotecan versus oxaliplatin/fluoropyrimidines for metastatic colorectal cancer with wild-type KRAS.
Hong YS; Kim HJ; Park SJ; Kim KP; Lee JL; Park JH; Kim JH; Lim SB; Yu CS; Kim JC; Baek JY; Kim SY; Kim TW
Cancer Sci; 2013 Apr; 104(4):473-80. PubMed ID: 23298313
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab in combination with cetuximab and irinotecan after failure of cetuximab and irinotecan in patients with metastatic colorectal cancer.
Larsen FO; Pfeiffer P; Nielsen D; Skougaard K; Qvortrup C; Vistisen K; Fromm AL; Jørgensen TL; Bjerregaard JK; Hoegdall E; Jensen BV
Acta Oncol; 2011 May; 50(4):574-7. PubMed ID: 21529301
[TBL] [Abstract][Full Text] [Related]
11. Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study.
André T; Blons H; Mabro M; Chibaudel B; Bachet JB; Tournigand C; Bennamoun M; Artru P; Nguyen S; Ebenezer C; Aissat N; Cayre A; Penault-Llorca F; Laurent-Puig P; de Gramont A;
Ann Oncol; 2013 Feb; 24(2):412-419. PubMed ID: 23041588
[TBL] [Abstract][Full Text] [Related]
12. Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximab.
Lee J; Hong YS; Hong JY; Han SW; Kim TW; Kang HJ; Kim TY; Kim KP; Kim SH; Do IG; Kim KM; Sohn I; Park SH; Park JO; Lim HY; Cho YB; Lee WY; Yun SH; Kim HC; Park YS; Kang WK
Invest New Drugs; 2014 Jun; 32(3):535-41. PubMed ID: 24468885
[TBL] [Abstract][Full Text] [Related]
13. Sensitivity to previous irinotecan treatment does not predict the efficacy of combination chemotherapy with cetuximab plus irinotecan for wild-type KRAS metastatic colorectal cancer.
Shitara K; Ura T; Matsuo K; Takahari D; Yokota T; Yuki S; Yoshida M; Utsunomiya S; Sato Y; Yamaura H; Kato M; Inaba Y; Tajika M; Kawai H; Yamazaki K; Komatsu Y; Muro K
Eur J Cancer; 2011 Dec; 47(18):2673-80. PubMed ID: 21652203
[TBL] [Abstract][Full Text] [Related]
14. Biweekly cetuximab plus FOLFIRI/irinotecan as first/second-line chemotherapy for patients with KRAS wild-type metastatic colorectal cancer: a retrospective analysis in Southwest Chinese population.
Chen Y; Cao D; Bi F; Li Q; Qiu M
Med Oncol; 2014 May; 31(5):935. PubMed ID: 24683007
[TBL] [Abstract][Full Text] [Related]
15. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial.
Seymour MT; Brown SR; Middleton G; Maughan T; Richman S; Gwyther S; Lowe C; Seligmann JF; Wadsley J; Maisey N; Chau I; Hill M; Dawson L; Falk S; O'Callaghan A; Benstead K; Chambers P; Oliver A; Marshall H; Napp V; Quirke P
Lancet Oncol; 2013 Jul; 14(8):749-59. PubMed ID: 23725851
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcome of Japanese metastatic colorectal cancer patients harbouring the KRAS p.G13D mutation treated with cetuximab + irinotecan.
Bando H; Yoshino T; Yuki S; Shinozaki E; Nishina T; Kadowaki S; Yamazaki K; Kajiura S; Tsuchihara K; Fujii S; Yamanaka T; Ohtsu A
Jpn J Clin Oncol; 2012 Dec; 42(12):1146-51. PubMed ID: 23071293
[TBL] [Abstract][Full Text] [Related]
17. A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: a pilot phase II trial.
Saridaki Z; Androulakis N; Vardakis N; Vamvakas L; Kabouraki E; Kalbakis K; Hatzidaki D; Voutsina A; Mavroudis D; Georgoulias V; Souglakos J
Br J Cancer; 2012 Dec; 107(12):1932-7. PubMed ID: 23169296
[TBL] [Abstract][Full Text] [Related]
18. Randomized phase 2 study of pegylated SN-38 (EZN-2208) or irinotecan plus cetuximab in patients with advanced colorectal cancer.
Garrett CR; Bekaii-Saab TS; Ryan T; Fisher GA; Clive S; Kavan P; Shacham-Shmueli E; Buchbinder A; Goldberg RM
Cancer; 2013 Dec; 119(24):4223-30. PubMed ID: 24105075
[TBL] [Abstract][Full Text] [Related]
19. Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial.
Ocvirk J; Brodowicz T; Wrba F; Ciuleanu TE; Kurteva G; Beslija S; Koza I; Pápai Z; Messinger D; Yilmaz U; Faluhelyi Z; Yalcin S; Papamichael D; Wenczl M; Mrsic-Krmpotic Z; Shacham-Shmueli E; Vrbanec D; Esser R; Scheithauer W; Zielinski CC
World J Gastroenterol; 2010 Jul; 16(25):3133-43. PubMed ID: 20593498
[TBL] [Abstract][Full Text] [Related]
20. Serum matrilysin correlates with poor survival independently of KRAS and BRAF status in refractory advanced colorectal cancer patients treated with irinotecan plus cetuximab.
Garcia-Albeniz X; Pericay C; Alonso-Espinaco V; Alonso V; Escudero P; Fernández-Martos C; Gallego R; Gascón P; Castellví-Bel S; Maurel J
Tumour Biol; 2011 Apr; 32(2):417-24. PubMed ID: 21104178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
